
Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE:GSK) on Monday to develop up to 12 medicines.
These agreements will add significant value to Hengrui’s globalization strategy and provide GSK with significant new growth opportunities beyond 2031.